

# Hemophilia & Bleeding Disorders

Burbank, CA P: (818) 848-8112 F: (818) 848-8142  
 Las Vegas, NV P: (702) 478-5133 F: (702) 478-5401



## PATIENT INFORMATION (Please complete the following or fax the patient demographic sheet)

Patient Name \_\_\_\_\_ DOB \_\_\_\_\_ Last Four of SS# \_\_\_\_\_ Sex:  Male  Female  
 Address \_\_\_\_\_ City, State, ZIP \_\_\_\_\_  
 Main Phone \_\_\_\_\_ Alternate Phone \_\_\_\_\_ Language Preference:  English  Spanish  Other \_\_\_\_\_

## PRESCRIBER INFORMATION

Prescriber's Name \_\_\_\_\_ Address \_\_\_\_\_  
 NPI \_\_\_\_\_ DEA \_\_\_\_\_ Lic \_\_\_\_\_ City, State, ZIP \_\_\_\_\_  
 Contact Person \_\_\_\_\_ Group/Hospital \_\_\_\_\_ Phone \_\_\_\_\_ Fax \_\_\_\_\_

## INSURANCE INFORMATION (Please fax a copy of patient's insurance card- both sides)

Prior Authorization Reference number \_\_\_\_\_

## CLINICAL INFORMATION

**Diagnosis** – Please include diagnosis name with ICD-10 code  
 D66 Hereditary factor VIII deficiency  D67 Hereditary factor IX deficiency  
 D68.0 Von Willebrand Disease-----  Type 1  Type 2  Type 3  
 Other: ICD-10 Code \_\_\_\_\_ Description \_\_\_\_\_  
**Date of Diagnosis** \_\_\_\_\_  
**Next Infusion Date** \_\_\_\_\_ Target Joints:  No  Yes \_\_\_\_\_  
**Infusion by\*:**  Parent  Patient  Other \_\_\_\_\_  
**Access:**  Peripheral  PICC  PORT  Other \_\_\_\_\_

Therapy:  New  Reauthorization  Restart  
 Weight: \_\_\_\_\_ kg / lb (circle) Height: \_\_\_\_\_ cm / in (circle)  
 Allergies:  NKDA  Other \_\_\_\_\_  
 Historical response:  High  Low Date: \_\_\_\_\_  
 Factor Deficiency:  Severe (<1%)  Moderate (1-5%)  Mild (>5%)  
 Circulating Factor: \_\_\_\_\_ % Inhibitor:  Low  Historical  Current  
 Comorbidities: \_\_\_\_\_  
 Concomitant medications: \_\_\_\_\_  
 \*Skilled nursing visits provided as needed

## PRESCRIPTION INFORMATION (Ancillary supplies provided as needed for administration)

Medication	Dose & Directions (Dose to be +/-10% unless specified)	Quantity	Refills
<b>Factor VIII (Recombinant)</b> <input type="checkbox"/> Advate® <input type="checkbox"/> Eloctate® <input type="checkbox"/> Kogenate FS® <input type="checkbox"/> Nuwiq® <input type="checkbox"/> Adynovate® <input type="checkbox"/> Esperoct® <input type="checkbox"/> Kovaltry® <input type="checkbox"/> Recombinate® <input type="checkbox"/> Afstyla® <input type="checkbox"/> Jivi® <input type="checkbox"/> Novoeight® <input type="checkbox"/> Xyntha®	Assay Variation: +/- _____%		
<b>Factor VIII (Human)</b> <input type="checkbox"/> Hemofil M® <input type="checkbox"/> Koate®	<input type="checkbox"/> Prophylaxis: _____	_____ Doses/month	_____
<b>Factor VIII and VWF **Dose will be dispensed in vWF:RCo units unless specified otherwise</b> <input type="checkbox"/> Alphanate® <input type="checkbox"/> Humate P®** <input type="checkbox"/> Vonvendi®** <input type="checkbox"/> Wilate®**	<input type="checkbox"/> Immune Tolerance: _____	_____ Doses/month	_____
<b>Factor IX</b> <input type="checkbox"/> AlphaNine® SD <input type="checkbox"/> Benefix® <input type="checkbox"/> Ixinity® <input type="checkbox"/> Rebinyn® <input type="checkbox"/> Alprolix® <input type="checkbox"/> Idelvion® <input type="checkbox"/> Mononine® <input type="checkbox"/> Rixubis®	<input type="checkbox"/> Breakthrough Bleeding: <input type="checkbox"/> Minor: _____ <input type="checkbox"/> Moderate: _____ <input type="checkbox"/> Major: _____	_____ Doses/month _____ Doses/month _____ Doses/month	_____
<b>Factor XIII</b> <input type="checkbox"/> Corifact® <input type="checkbox"/> Tretten®	<input type="checkbox"/> Other: _____	_____ Doses/month	_____
<b>Inhibitor Therapies, Factor VIIa, and other</b> <input type="checkbox"/> Feiba® <input type="checkbox"/> NovoSeven® <input type="checkbox"/> Other: _____			
<b>Hemlibra®</b> <input type="checkbox"/> 30mg/mL <input type="checkbox"/> 60mg/0.4mL <input type="checkbox"/> 105mg/0.7mL <input type="checkbox"/> 150mg/mL	<input type="checkbox"/> Initial dose: 3mg/kg subQ once weekly for 4 weeks <input type="checkbox"/> Maintenance dose: 1.5mg/kg subQ once weekly <input type="checkbox"/> Maintenance dose: 3mg/kg subQ every 2 weeks <input type="checkbox"/> Maintenance dose: 6mg/kg subQ every 4 weeks <input type="checkbox"/> Other: _____		
<input type="checkbox"/> EMLA® Cream, 30gm <input type="checkbox"/> Other: _____			
<input type="checkbox"/> EPIPEN® 0.3mg <input type="checkbox"/> EPIPEN Jr® 0.15mg	<input type="checkbox"/> Inject as needed for anaphylaxis		
<b>Stimate®</b> <input type="checkbox"/> 150mcg/actuation nasal spray	<input type="checkbox"/> Wt<50kg, single spray in <b>one</b> nostril (1 spray total) <input type="checkbox"/> Wt>50kg, single spray in <b>each</b> nostril (2 sprays total)		
<b>Amicar®</b> <input type="checkbox"/> 500mg tablets <input type="checkbox"/> 25% Oral Solution			
<b>Lysteda®</b> <input type="checkbox"/> 650mg tablets			
<b>Flushing</b> <input type="checkbox"/> 0.9% Normal Saline Flush, 5-10mL pre and post IV medication administration <input type="checkbox"/> Heparin 10units/mL Flush, 3-5mLs as needed <input type="checkbox"/> Heparin 100units/mL Flush, 1-3mLs as needed		<input type="checkbox"/> Quantity Sufficient <input type="checkbox"/> PRN <input type="checkbox"/> _____ <input type="checkbox"/> _____	

\*Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Deliver to:  Patient  Office  Other \_\_\_\_\_ Needs by Date: \_\_\_\_\_

Prescriber's Signature \_\_\_\_\_ Date \_\_\_\_\_  Substitution permitted unless this box is checked

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.